Concepedia

Katherine Liau

KL

Statistics

Publications

26

Citations

2.5K

H-Index

19

Active since

2004

Affiliations

Pfizer (United States)(Current)

Fox Chase Cancer Center

University of Chicago

Moffitt Cancer Center

Cleveland Clinic

Katherine Liau is an author at Pfizer (United States) specializing in oncology, medicine, and pharmacology.

Publications per year

2004–2021

26

Publications

26

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al. · Journal of Clinical Oncology · 2008 · 622 citations · Full text

, , +14

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson et al. · The Lancet Oncology · 2007 · 436 citations

, , +14

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

Jean‐Philippe Spano, Catherine Chodkiewicz, Joan Maurel et al. · The Lancet · 2008 · 249 citations

, , +8

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

Joan H. Schiller, Timothy Larson, S.-H.I. Ou et al. · Journal of Clinical Oncology · 2009 · 174 citations · Full text

, , +15

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein et al. · Blood Advances · 2017 · 131 citations · Full text

, , +17

1–5 of 26